CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES ›› 2020, Vol. 38 ›› Issue (3): 370-377.doi: 10.12140/j.issn.1000-7423.2020.03.018
• REVIEWS • Previous Articles Next Articles
ZHAO Jin-ying1, LIU Peng2, LI Yan-wei1,2, WANG Shi-ping3,*()
Received:
2019-08-16
Online:
2020-06-30
Published:
2020-07-07
Contact:
Shi-ping WANG
E-mail:wsp4373383@126.com
Supported by:
CLC Number:
ZHAO Jin-ying, LIU Peng, LI Yan-wei, WANG Shi-ping. Research progress on combined medications for schistosomiasis[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2020, 38(3): 370-377.
[1] |
Colley DG, Bustinduy AL, Secor WE, et al. Human schistosomiasis[J]. Lancet, 2014,383(9936):2253-2264.
doi: 10.1016/S0140-6736(13)61949-2 pmid: 24698483 |
[2] |
Caffrey CR. Chemotherapy of schistosomiasis: present and future[J]. Curr Opin Chem Biol, 2007,11(4):433-439.
doi: 10.1016/j.cbpa.2007.05.031 pmid: 17652008 |
[3] |
Mäder P, Rennar GA, Ventura AMP, et al. Chemotherapy for fighting schistosomiasis: past, present and future[J]. Chem Med Chem, 2018,13(22):2374-2389.
doi: 10.1002/cmdc.201800572 pmid: 30212614 |
[4] | Xiao SH. Study progress on the mode of action of praziquantel against schistosomes[J]. Chin J Parasitol Parasit Dis, 2007,25(6):492-502. (in Chinese) |
( 肖树华. 吡喹酮抗血吸虫作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2007,25(6):492-502.) | |
[5] |
Vale N, Gouveia MJ, Rinaldi G, et al. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance[J]. Antimicrob Agents Chemother, 2017,61(5). e02582-e02598.
doi: 10.1128/AAC.02582-16 pmid: 28264841 |
[6] |
da Silva VBR, Campos BRKL, de Oliveira JF, et al. Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine[J]. Bioorg Med Chem, 2017,25(13):3259-3277.
doi: 10.1016/j.bmc.2017.04.031 pmid: 28495384 |
[7] |
Valentim CLL, Cioli D, Chevalier FD, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites[J]. Science, 2013,342(6164):1385-1389.
doi: 10.1126/science.1243106 pmid: 24263136 |
[8] | Shaw JR, Brammer KW. The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel[J]. Trans Royal Soc Trop Med Hyg, 1983,77(1):39-40. |
[9] | Botros S, Soliman A, El-Gawhary N, et al. Effect of combined low dose praziquantel and oxamniquine on different stages of schistosome maturity[J]. Trans Royal Soc Trop Med Hyg, 1989,83(1):86-89. |
[10] |
Delgado VS, Suarez DP, Cesari IM, et al. Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite[J]. Parasitol Res, 1992,78(8):648-654.
doi: 10.1007/BF00931515 pmid: 1480600 |
[11] |
Pugh RN, Teesdale CH. Synergy of concurrent low dose oxamniquine and praziquantel in schistosomiasis[J]. BMJ, 1983,287(6396):877-878.
doi: 10.1136/bmj.287.6396.877 pmid: 6412867 |
[12] |
Creasey AM, Taylor P, Thomas JE. Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean school children[J]. Cent Afr J Med, 1986,32(7):165-167.
pmid: 3107836 |
[13] |
Shuhua X, Hotez PJ, Tanner M. Artemether, an effective new agent for chemoprophylaxis against shistosomiasis in China: its in vivo effect on the biochemical metabolism of the Asian schistosome[J]. Southeast Asian J Trop Med Public Health, 2000,31(4):724-732.
pmid: 11414420 |
[14] |
El-Lakkany NM, Seif el-Din SH. Haemin enhances the in vivo efficacy of artemether against juvenile and adult Schistosoma mansoni in mice[J]. Parasitol Res, 2013,112(5):2005-2015.
doi: 10.1007/s00436-013-3358-7 |
[15] |
Pérez del Villar L, Burguillo FJ, López-Abán J, et al. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis[J]. PLoS One, 2012,7(9):e45867.
doi: 10.1371/journal.pone.0045867 pmid: 23029285 |
[16] |
Xiao SH, You JQ, Mei JY, et al. Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits[J]. Parasitol Int, 2000,49(1):25-30.
pmid: 10729714 |
[17] |
Utzinger J, Chollet J, You JQ, et al. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals[J]. Acta Trop, 2001,80(1):9-18.
pmid: 11495639 |
[18] |
Mahmoud MR, Botros SS. Artemether as adjuvant therapy to praziquantel in murine Egyptian schistosomiasis mansoni[J]. J Parasitol, 2005,91(1):175-178.
doi: 10.1645/GE-322R pmid: 15856895 |
[19] | Hou XY, McManus DP, Gray DJ, et al. A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China[J]. Bull World Health Organ, 2008,86(10):788-795. |
[20] |
Abdin AA, Ashour DS, Shoheib ZS. Artesunate effect on schistosome thioredoxin glutathione reductase and cytochrome c peroxidase as new molecular targets in Schistosoma mansoni-infected mice[J]. Biomed Environ Sci, 2013,26(12):953-961.
doi: 10.3967/bes2013.030 pmid: 24393504 |
[21] | Clercq D, Vercruysse J, Verle P, et al. What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?[J]. Trop Med Int Health, 2000,5(10):744-746. |
[22] | Inyang-Etoh PC, Ejezie GC, Useh MF, et al. Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria[J]. Trans Royal Soc Trop Med Hyg, 2009,103(1):38-44. |
[23] | Yunusa EU, Awosan KJ, Ibrahim MTO, et al. Comparative cure rates of artesunate-praziquantel combination and praziquantel monotherapy in the control of urinary schistosomiasis among “Almajiri” school children in Sokoto, Nigeria.[J]. Int Res J Basic Clin Stud, 2016,5:5-9. |
[24] | Sissoko MS, Dabo A, Traoré H, et al. Efficacy of artesunate +sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children[J]. PLoS One, 2009,4(10):e6732. |
[25] | Wang JY, Ding DB, Li GF, et al. Therapeutic efficacy of naphthoquine phosphate combined with artemisinine against Plasmodium knowlesi[J]. Chin J Parasitol Parasit Dis, 2008,26(6):442-444. (in Chinese) |
( 王京燕, 丁德本, 李国福, 等. 磷酸萘酚喹伍用青蒿素对猴疟原虫的药效学研究[J]. 中国寄生虫学与寄生虫病杂志, 2008,26(6):442-444.) | |
[26] |
El-Beshbishi SN, Taman A, El-Malky M, et al. First insight into the effect of single oral dose therapy with artemisinin-naphthoquine phosphate combination in a mouse model of Schistosoma mansoni infection[J]. Int J Parasitol, 2013,43(7):521-530.
doi: 10.1016/j.ijpara.2013.01.007 |
[27] |
Van Nassauw L, Toovey S, Van Op den Bosch J, et al. Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice[J]. Travel Med Infect Dis, 2008,6(5):253-258.
pmid: 18760248 |
[28] | Xiao SH, Xue J. Study progress on mefloquine against schistosomes and other helminths[J]. Chin J Parasitol Parasit Dis, 2012,30(2):131-138, 145. (in Chinese) |
( 肖树华, 薛剑. 甲氟喹抗血吸虫及其他蠕虫作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2012,30(2):131-138, 145.) | |
[29] | Xiao SH, Mei JY, Jiao PY. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum[J]. Parasitol Res, 2011,108(2):399-406. |
[30] |
Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro[J]. J Antimicrob Chemother, 2011,66(8):1791-1797.
doi: 10.1093/jac/dkr178 pmid: 21602552 |
[31] | Nashwa SA, Naglaa SA. Evaluation of mefloquine-praziquantel combination therapy in pre-patent and patent Schistosoma mansoni infection in mice[J]. Sci Parasitol, 2011,12(3):139-149. |
[32] |
Keiser J, N′Guessan NA, Adoubryn KD, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial[J]. Clin Infect Dis, 2010,50(9):1205-1213.
doi: 10.1086/651682 pmid: 20350194 |
[33] |
Keiser J, Silué KD, Adiossan LK, et al. Praziquantel, mefloquine-praziquantel, and mefloquine-artesunate-praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial[J]. PLoS Negl Trop Dis, 2014,8(7):e2975.
pmid: 25033291 |
[34] |
Mossallam SF, Amer EI, El-Faham MH. Efficacy of Synriam?, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni[J]. Acta Trop, 2015,143:36-46.
doi: 10.1016/j.actatropica.2014.12.005 pmid: 25530543 |
[35] | Portela J, Boissier J, Gourbal B, et al. Antischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoni[J]. PLoS Negl Trop Dis, 2012,6(2):e1474. |
[36] | El Kouni MH, Diop D, O′Shea P, et al. Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5′-monophosphate for the treatment of schistosomiasis[J]. Antimicrob Agents Chemother, 1989,33(6):824-827. |
[37] | El Kouni MH, Knopf PM, Cha S. Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5′-monophosphate[J]. Biochem Pharmacol, 1985,34(21):3921-3923. |
[38] | El Kouni MH, Messier NJ, Cha S. Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors[J]. Biochem Pharmacol, 1987,36(22):3815-3821. |
[39] | Sulaiman SM, Ali HM, Homeida MM, et al. Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops)[J]. Trop Med Parasitol, 1989,40(3):335-336. |
[40] | Mahmoud M, Zoheiry M, Nosseir M. Effect of combined chemotherapy and anti-inflammatory drugs on murine schistosomiasis[J]. Arzneimittelforschung, 2011,52(4):294-301. |
[41] | Yepes E, Varela-M RE, López-Abán J, et al. Inhibition of granulomatous inflammation and prophylactic treatment of schistosomiasis with a combination of edelfosine and praziquantel[J]. PLoS Negl Trop Dis, 2015,9(7):e0003893. |
[42] | Yepes E, Varela-M RE, López-Abán J, et al. In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine[J]. PLoS One, 2014,9(10):e109431. |
[43] |
Hassan S, Ali I, Nessim N, et al. Treatment of acute Schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice[J]. Arzneimittelforschung, 2011,53(6):440-444.
pmid: 12872615 |
[44] | Botros S, Mahmoud M, Hammam O, et al. Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates[J]. Apmis, 2006,114(7/8):480-491. |
[45] | Soliman MFM, Ibrahim MM. Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study[J]. Acta Trop, 2005,93(1):1-9. |
[46] | Chen GZ, Foster L, Bennett J. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival[J]. Naunyn-Schmiedeberg’s Arch Pharmacol, 1990,342(4):477-482. |
[47] | Rojo-Arreola L, Long T, Asarnow D, et al. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis[J]. PLoS One, 2014,9(1):e87594. |
[48] |
Rizk M, Ibrahim N, El-Rigal N. Comparative in vivo antioxidant levels in Schistosoma mansoni infected mice treated with praziquantel or the essential oil of Melaleuca armillaris leaves[J]. Pak J Biol Sci, 2012,15(20):971-978.
doi: 10.3923/pjbs.2012.971.978 pmid: 24199475 |
[49] |
De Oliveira RN, Rehder VLG, Santos Oliveira AS, et al. Schistosoma mansoni: in vitro schistosomicidal activity of essential oil of Baccharis trimera (less) DC[J]. Exp Parasitol, 2012,132(2):135-143.
doi: 10.1016/j.exppara.2012.06.005 pmid: 22771865 |
[50] |
Elsammak MY, Al-Sharkaweey RM, Ragab MS, et al. IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease[J]. Parasite Immunol, 2008,30(11-12):603-609.
doi: 10.1111/j.1365-3024.2008.01061.x pmid: 19067841 |
[51] | McCormick ML, Metwali A, Railsback MA, et al. Eosinophils from schistosome-induced hepatic granulomas produce superoxide and hydroxyl radical[J]. J Immunol, 1996,157(11):5009-5015. |
[52] | Soliman RH, Ismail OA, Badr MS, et al. Resveratrol ameliorates oxidative stress and organ dysfunction in Schistosoma mansoni infected mice[J]. Exp Parasitol, 2017,174:52-58. |
[53] |
De Paula AD, Brunetto MMM, Rezende ME, et al. Curcumin generates oxidative stress and induces apoptosis in adult Schistosoma mansoni worms[J]. PLoS One, 2016,11(11):e0167135.
doi: 10.1371/journal.pone.0167135 pmid: 27875592 |
[54] |
Kamel ROA, El-Shinnawy NA. Immunomodulatory effect of garlic oil extract on Schistosoma mansoni infected mice[J]. Asian Pac J Trop Med, 2015,8(12):999-1005.
doi: 10.1016/j.apjtm.2015.11.016 pmid: 26706670 |
[55] |
De Lima AA, de Azevedo AMC, Silva RA, et al. Immunohistopathological changes in murine Schistosomiasis mansoni under the influence of N-acetyl-L-cysteine[J]. Parasitol Res, 2012,111(4):1569-1578.
doi: 10.1007/s00436-012-2997-4 pmid: 22773008 |
[1] | LI Jie, WEN Yusong, LI Zhaojun. Effect of tourism development on schistosomiasis control in China [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023, 41(3): 355-360. |
[2] | CHEN Lin, ZHU Jifeng, QIU Jingfan, XU Zhipeng, ZHANG Donghui, CHEN Lu, HE Jian, LI Wei, YANG Kun, JI Minjun. Design and development of a virtual simulation project for schistosomiasis control based on the One Health concept [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2023, 41(1): 81-84. |
[3] | FENG Jia-xin, GONG Yan-feng, LUO Zhuo-wei, WANG Wei, CAO Chun-li, XU Jing, LI Shi-zhu. Scientific basis of strategies for schistosomiasis control and prospect of the 14th Five-Year Plan in China [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(4): 428-435. |
[4] | CHEN Bing, ZHANG Guo-li, ZHANG Gao-hong. Research progress on clinical trials of schistosomiasis vaccine candidates [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(4): 511-515. |
[5] | OUYANG Bing, LI Ren-xi. One case of Diphyllobothrium latum infection caused by raw salmon [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(3): 295-298. |
[6] | XIE Hui-qun, XU Yun, GONG Zhi-hong, HU Fei, WAN Hui, XU Chun-hua, WU Jie, LIU Jun-pu, HONG Dao-jun. Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(2): 204-210. |
[7] | GAO Yuan, HU Yuan, CAO Jian-ping. Research progress on the role of immune cells in liver fibrosis due to schistosomiasis [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2022, 40(1): 88-93. |
[8] | GUO Su-ying, ZHU Hong-qing, CAO Chun-li, DENG Wang-ping, BAO Zi-ping, JIA Tie-wu, LI Yin-long, LV Chao, QIN Zhi-qiang, ZHANG Li-juan, FENG Ting, YANG Fan, LV Shan, XU Jing, LI Shi-zhu. Risk assessment of schistosomiasis transmission along the middle and lower reaches of Yangtze River after flooding in 2020 [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(6): 753-758. |
[9] | SHI Liang, XIONG Chun-rong, LIU Mao-mao, WEI Xiu-shen, ZHANG Jian-feng, WANG Xin-yao, WANG Tao, HANG De-rong, YANG Hai-tao, YANG Kun. Evaluation of efficacy of visual intelligent recognition model for Oncomelania hupensis based on deep learning technology [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(6): 764-770. |
[10] | LI Bo, ZHANG Cong, SHAN Xiao-wei, YI Jia, TU Zhen, HE Hui, TANG Li, ZHU Hong, LIU Jian-bing. Evaluation of the pathogen detection capacity in standardized schistosomiasis laboratories in Hubei Province [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(5): 572-576. |
[11] | WU Jia-li, LI Bo, LIU Si, TU Zu-wu, TANG Li, TU Zhen, ZHOU Xiao-rong, SUN Ling-cong, XIAO Ying, ZHU Hong. Assessment of transmission risk of human schistosomiasis japonica based on human population antibody level in Hubei Province [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(5): 578-584. |
[12] | HU Fei, GAO Zhu-lu, YUAN Min, LI Zhao-jun, LI Yi-feng, LIU Yue-min, LI Jian-ying, XIE Shu-ying, WEN Yu-song, LIN Dan-dan. Changing trends of schistosome infection and liver fibrosis among residents in the Poyang Lake region [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(5): 629-636. |
[13] | LIU Rong, ZHANG Jian-feng, YAN Xiao-lan, WEN Li-yong. Comparative study of SF-36 and EQ-5D-5L in evaluating quality of life for patients with advanced schistosomiasis [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(5): 639-645. |
[14] | LIU Rong, WEN Li-yong. New progress in basic and clinical research of advanced schistosomiasis [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(4): 429-436. |
[15] | HONG Zhong, WU Ling-ling, WANG Li-ping, XU Jing. Progress and challenges on global schistosomiasis control [J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2021, 39(4): 514-519. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 312
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 634
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||